Literature DB >> 23179105

Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study.

Nadja Fratzl-Zelman1, Paul Roschger, John E Fisher, Le T Duong, Klaus Klaushofer.   

Abstract

Odanacatib (ODN) has been developed as a selective inhibitor of cathepsin K, the major cysteine protease in osteoclasts. In adult rhesus monkeys, treatment with ODN prevents ovariectomy-induced bone loss in lumbar vertebrae and hip. In this study, we evaluate the effects of ODN on bone mineralization density distribution (BMDD) by quantitative backscattered electron imaging in vertebral spongiosa, distal femoral metaphyseal and cortical shaft from monkeys (aged 16-23 years), treated with vehicle (n=5) or ODN (6 mg/kg, n=4 or 30 mg/kg, n=4, PO daily) for 21 months. Dual-energy X-ray absorptiometry was measured in a subset of distal femoral samples. In lumbar vertebrae there was a shift to higher mineralization in samples from ODN-treated groups, compared to vehicle: CaMean (+4%), CaPeak (+3%), CaWidth (-9%), CaLow (-28%) in the 6 mg/kg group and CaMean (+5.1%, p<0.023), CaPeak (+3.4%, p<0.046), CaWidth (-15.7%, p=0.06) and CaLow (-38.2%, p<0.034) in the 30 mg/kg group. In distal femoral metaphyseal cancellous bone, there was a clear tendency toward a dose-dependent increase in matrix mineralization, as in the spine. However, primary and osteonal bone of the distal cortical diaphyses showed no significant change in BMDD, whereas bone mineral density was significantly increased after treatment. In ovariectomized monkeys, this study shows that ODN treatment increased trabecular BMDD, consistent with its previously reported ability to reduce cancellous remodeling. Here, ODN also showed no changes in BMDD in cortical bone sites, consistent with its actions on maintaining endocortical and stimulating periosteal bone formation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179105     DOI: 10.1007/s00223-012-9673-7

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  10 in total

Review 1.  Bone composition: relationship to bone fragility and antiosteoporotic drug effects.

Authors:  Adele L Boskey
Journal:  Bonekey Rep       Date:  2013-12-04

2.  Validation of cortical bone mineral density distribution using micro-computed tomography.

Authors:  Maleeha Mashiatulla; Ryan D Ross; D Rick Sumner
Journal:  Bone       Date:  2017-03-29       Impact factor: 4.398

Review 3.  Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.

Authors:  Matthew T Drake; Bart L Clarke; Merry Jo Oursler; Sundeep Khosla
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 4.  Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects.

Authors:  Barbara M Misof; Nadja Fratzl-Zelman; Eleftherios P Paschalis; Paul Roschger; Klaus Klaushofer
Journal:  Bonekey Rep       Date:  2015-02-11

Review 5.  Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.

Authors:  Natalie A Sims; Kong Wah Ng
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

Review 6.  Changes in the degree of mineralization with osteoporosis and its treatment.

Authors:  Paul Roschger; Barbara Misof; Eleftherios Paschalis; Peter Fratzl; Klaus Klaushofer
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

Review 7.  Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.

Authors:  J Y Reginster; A Neuprez; C Beaudart; M P Lecart; N Sarlet; D Bernard; S Disteche; O Bruyere
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

8.  Effects of odanacatib on bone matrix mineralization in rhesus monkeys are similar to those of alendronate.

Authors:  Barbara M Misof; Paul Roschger; Charles Chen; Maureen Pickarski; Phaedra Messmer; Klaus Klaushofer; Le T Duong
Journal:  Bone Rep       Date:  2016-03-06

9.  Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats.

Authors:  Chun Yi; Ke-Yi Hao; Ting Ma; Ye Lin; Xi-Yuan Ge; Yu Zhang
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379

10.  Cathepsin K inhibition preserves compressive load in lumbar vertebrae of osteoporotic monkeys.

Authors:  Isabel D Colón-Bernal; Le T Duong; Brenda Pennypacker; James Henderson; Kenneth M Kozloff; Mark M Banaszak Holl
Journal:  Bone Rep       Date:  2018-10-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.